The landscape of cancer treatment has changed dramatically in the last seven years, beginning with the approval of Ipilmumab in 2011, the first immunotherapy drug. Efforts to unsheathe the tumour cells of their protective microenvironment and expose them to an active immune response have delivered several monoclonal antibodies (mAbs) that…
List view / Grid view
Cell line development – global market drivers, trends and its impact on improving biologics development from early phase to IND during the drug discovery process
19 March 2019 | By Aparajita Dubey - Associate Consultant at Prescient Healthcare Group
Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in-vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. This stage involves the production of recombinant proteins such as monoclonal antibodies, bi-specific…
18 February 2019 | By Tecan and Ncardia
Ncardia, will discuss the application of human iPSC-derived cell-based assays and high throughput screening for drug discovery and development.
Three-dimensional cell cultures (spheroids, organoids) are becoming widely used as a new predictive tool in early drug discovery. The use of 3D cell cultures is believed to provide a more physiologically relevant response than monolayer (2D) cell cultures because they closely mimic the extracellular matrix and cell-cell interactions that occur…
5 December 2018 | By BMG Labtech GmbH
The Small Molecule Screening Facility (SMSF) at the University of Wisconsin Madison is a comprehensive high-throughput screening (HTS) centre where researchers have investigated antibiotic-resistant bacterial infections and screening for protein-protein interactions using HTS methods.
A high-throughput approach for measuring intracellular ATP levels to access compound-mediated cellular toxicity
30 November 2018 | By Maria Kuzikov (Fraunhofer-IME SP), Oliver Keminer (Fraunhofer Institute for Molecular Biology and Applied Ecology), Salma Hachim (Fraunhofer Institute for Molecular Biology and Applied Ecology), Sheraz Gul (Fraunhofer-IME SP)
Many drugs fail in clinical trials due to toxicity-related issues; therefore, drug-mediated cellular toxicity should be determined at an early stage in the drug discovery value chain. There are many assay systems that can be utilised to measure cellular toxicity. In this article we demonstrate that intracellular ATP concentrations are…
Application note: Production of human induced pluripotent stem cell-derived cortical neurospheres in the DASbox® Mini Bioreactor System
29 November 2018 | By Eppendorf
There is substantial interest in the scientific community in using human induced pluripotent stem cell (hiPSC)-derived neural cells to study basic mechanisms of brain development, neuronal function, and drug-induced effects. In vitro-generated brain organoids are promising models, because they show a remarkable degree of maturation and can be kept in…
29 November 2018 | By Thermo Fisher Scientfic
This technical note demonstrates the feasibility of using the Thermo Scientific™Fluoroskan™ or Fluoroskan FL instruments with the Invitrogen™ Quant-iT™ dsDNAhigh-sensitivity assays. Sensitive and specific quantification of double-stranded DNA is carried out in microplate format. This is part of a series of technical notes aiming to help customers choose the best…
29 November 2018 | By IntelliCyt Corporation
With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.
Application note: Direct measurements of cellular metabolism for identification of mitochondrial drug targets
Drug target identification has a key role in the drug discovery value chain. A critical step in the development of pharmaceuticals is identifying the direct targets of potential drug candidates as well as distinguishing any secondary or off-target effects...
High throughput screening for deep mining of antibody repertoires, Dr. Stefan Moese, Novartis, Switzerland
9 November 2018 | By Beckman Coulter
In this webinar you learn about a high throughput screening approach for mining of antibody repertoires in the context of biologics drug discovery.
30 October 2018 | By BMG Labtech GmbH
In this webinar, we presented two examples of HTS in 1536-well plates, a screen for protein-protein interactions and a cell-based luciferase reporter assay.
19 October 2018 | By Thermo Fisher Scientfic
This application note aims to demonstrate the benefits of using orthogonal approaches for studying Staphylococcus aureus biofilms—in particular, their susceptibility to antimicrobial agents...
12 September 2018 | By BMG Labtech GmbH
This webinar shines a spotlight on cell-based and biochemical high-throughput screening in 1536 well plates. Supported by BMG LABTECH, the webinar will take place on 30 October at 4:00pm (GMT).
This webinar, held on 28 June 2018, illustrated the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation. Keynote speaker Arsenio Nueda, Head of Molecular Biology at Almirall, responded as follows to questions posed during the webinar.